Astellas Pharma Inc. and XenoPort, Inc. Announce the Launch of Regnite® Tablets for Restless Legs Syndrome in Japan
TOKYO & SANTA CLARA, Calif.--(BUSINESS WIRE)--Astellas Pharma Inc. (Tokyo: 4503) and XenoPort, Inc. (NASDAQ: XNPT) announced today that Regnite® (gabapentin enacarbil) Extended-Release Tablets will be launched in Japan on July 10, 2012. Regnite is approved in Japan for the treatment of moderate-to-severe primary restless legs syndrome (RLS). Astellas’ promotional efforts will focus on sleep and neurology specialists. Approximately 1,200 Astellas sales representatives will participate in the promotion of Regnite.